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Background: To estimate the disability-adjusted life years (DALY) in a nationwide representative sample of
postmenopausal women with osteoporosis. The effects of drug-based therapy and risk factors for osteoporotic
bone fractures on DALY losses were also explored.
Methods: DALY were estimated based on participant’s clinical characteristics and Health-Related Quality-of-Life
(HRQoL) data obtained from a cross-sectional, epidemiological one-visit study (the GINERISK study). The study
enrolled postmenopausal women (at least 12-months after their last menstrual period) with osteoporosis,
above 18-years old, who attended Spanish outpatient Gynaecology clinics. HRQoL was assessed using the
generic SF-12v2 questionnaire, which was used to derive disutility values. Mortality rates were extracted from
the Spanish national statistics database. Factors explored to be associated with DALY losses were examined
using ANOVA, ANCOVA and MANCOVA models.
Results: DALY could be computed in 2,782 (67%) out of 4,157 postmenopausal women, with a mean (95%
CI) age of 61.0 (60.7-61.2) years. Overall individual undiscounted DALY per woman were 6.1 (5.9-6.2), resulting
to be significantly higher in women with severe osteoporosis with prior bone fracture; 7.8 (7.2-8.4) compared
to osteoporotic women [5.8 (5.6-6.0)] or postmenopausal women with a BMD > −2.5 T-score that received a
drug-based therapy [6.2 (5.8-6.5)]; F = 27.0 (P < 0.01). Models explaining the variation in the levels of health
based on the use of a selective estrogen receptor modulator (SERM) or possession of risk factors for osteoporotic
BF were found (P < 0.05).
Conclusions: DALY losses were considerable amongst postmenopausal women with osteoporosis. Not having a prior
bone fracture, being older, using a SERM and having less osteoporotic risk factors were all linked to less DALY losses.
Keywords: Disability-adjusted life year, Burden of illness, Osteoporosis, Menopause, Disability weights, Drug-based
therapy, Osteoporotic risk fracture factorsBackground
Osteoporosis is a major public health problem character-
ized by a loss of bone mineral density (BMD) associated
with fragility fractures [1-3]. In developed countries
osteoporosis-associated fractures form one relevant
cause of mortality and a major cause of disability for
post-menopausal women [4,5]. Patients having osteopor-
osis that experienced bone fractures showed to have a* Correspondence: darba@ub.edu
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unless otherwise stated.decrease in health related quality of life (HRQoL) due to
pain, deformity and/or disability, as well as death [6].
Therefore it is important to focus attention on the
identification of women with a high risk of fragility frac-
ture, apart from the identification of patients with osteo-
porosis, which are usually diagnosed exclusively by BMD
according to WHO criteria. These four general diagnostic
categories for women [7-9] expressed in relation to a refer-
ence population in standard deviation (SD) units proposed
include: normal, with a BMD of less than 1 SD below the
reference population (T-score > −1); osteopenia, with a
BMD of more than 1 SD below the reference populationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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osis, with a BMD of 2.5 SD or higher (T-score ≤ −2.5)
below the reference population; severe osteoporosis with a
BMD value of 2.5 SD or higher below the mean of the ref-
erence population in the presence of one or more fragility
fractures.
Although BMD is an important component of bone
fracture risk, several other risk factors have also been
demonstrated to affect the risk of bone fractures. These
risk factors include but are not limited to age, a prior fra-
gility fracture, a parental history of hip fracture, smoking,
the use of systemic corticosteroids, excess alcohol use,
rheumatoid arthritis, low body weight, etc., [10]. The inde-
pendent contribution of each of these risk factors can be
integrated to estimate fracture probability with or without
the use of BMD and should be taken into account when
performing a global risk evaluation [11].
At a global level several studies have quantified the bur-
den of osteoporosis [12-14] which is based on the most
important consequences of osteoporosis, in specific on
fragility fractures. For this reason, fractures are a measure
of the disease burden of osteoporosis. But the problem is
that this measure is imprecise as fractures are a specific
state in themselves which are associated with further bur-
densome consequences like losses of functioning and fear
[15]. Therefore information on disability and fatal conse-
quences as life-years lost due to premature mortality are
more important information which is combined in disability-
adjusted life years (DALY). Premature mortality entails esti-
mating the average time a person would have lived had he
or she not died prematurely [16]. This estimation inher-
ently incorporates age and death, rather than merely the
occurrence of death itself [17]. To date, individual DALY
losses due to osteoporosis for Spanish postmenopausal
women have not been estimated.
The aim of this study was to estimate individual DALY
losses based on participants’ clinical characteristics and
HRQoL data collected in a cross-sectional, epidemio-
logical one-visit study, called the GINERISK study [18],
among a nationwide representative sample of postmeno-
pausal women with osteoporosis. As described earlier
several factors have been demonstrated to affect bone
fracture risk [5], and therefore may affect health levels of
osteoporotic women. Therefore the relationship between
drug-based therapy and risk factors for osteoporotic
bone fracture was also explored, to determine its associ-
ation with improvements in the health levels of these
postmenopausal osteoporotic women, in terms of more
or less DALY losses.
Methods
Study sample and methods of sampling
Participant data used for the estimation of DALY losses
was extracted from the GINERISK study [18]. In brief,this was a nationwide study carried out during 2011 at out-
patient clinics of Gynaecology in Spain. Postmenopausal
women above 18 years of age attending these clinics were
invited to participate in the study. Inclusion criteria
for the study were being a postmenopausal woman (last
menstruation over more than 12 months, either nat-
ural menopause or surgically- or drug-induced meno-
pause) with a diagnosis of osteoporosis (spinal BMD
T-score < −2,5 according to the WHO criteria and identi-
fied by Bone Densitometry - DXA) within two years prior
to the study visit. All participants had to sign an informed
consent form.
Among the women who underwent a DXA during
the study visit, around 20% were diagnosed to be non-
osteoporotic according to the WHO criteria. However,
these women had been diagnosed with osteoporosis
within the last 2 years (according to the inclusion cri-
teria in the study) and received treatment under supervi-
sion of their gynecologist for their condition, which
subsequently lead to reversal of their condition at the time
of the Ginerisk one-visit study. Participants were excluded
if they received treatment with hormones or any other
psychopharmacologic agent, or if they were not able to
understand patient-reported-outcomes questionnaires writ-
ten in Spanish for any reasons.
A stratified multistage probability sample without re-
placement was drawn. The sampling frame included all
health regions of the 17 Autonomous Communities
within Spain. The first stage consisted of the selection of
Gynecology clinics within each health region. The num-
ber of selected clinics in each region was proportional to
the population density of the specific region. In the sec-
ond stage, one gynecologist per clinic was chosen at ran-
dom among those who had previously participated in
clinical and/or epidemiological research in the field of
gynecology, and invited to participate. The third stage
consisted of participant selection with a systematic sam-
pling strategy from the daily list of all participants that
had an appointment with each of the participating gyne-
cologists and that had met the previously mentioned in-
clusion criteria.
During one single visit the gynaecologists completed
the individual case report forms (CRFs) with information
collected from a questionnaire administered by the same
gynaecologist. Supplementary data obtained from partici-
pant’s records on socio-demographics, clinical characteris-
tics, medication utilization, and HRQoL was also collected.
Medication utilization related to osteoporosis was col-
lected from the patients’ medical record and included the
following type of therapies to treat osteoporosis: calcium
supplement, calcium+ vitamin D, bisphosphonates, select-
ive estrogen receptor modulators (SERM) or other drugs.
Information on regular physical exercise was asked dir-
ectly to the participant. In addition to the required initial
Darbà et al. BMC Public Health  (2015) 15:324 Page 3 of 10diagnose of osteoporosis using a DXA, BMD was also
measured during the study visit using a DXA. According
to the current values obtained by DXA (T-score) and the
WHO criteria, all women were re-classified into three
groups: osteoporosis (T-score ≤ −2.5), severe osteopor-
osis (T-score ≤ −2.5 in the presence of one or more
prior bone fractures) and women with a T-score > −2.5.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and was approved
by the Ethical Committee of the Hospital de la Princesa
in Madrid.Sample size
The sample size was established following the guidelines
of the International Conference on Harmonization [18],
in order to be able to draw firm conclusions in relation
to the established study objectives in the original, or
GINERISK study and no adjustments were carried out
for the analysis included here. Nevertheless, calculations
were carried out posteriori to recalculate the sample
power. This recalculation showed that the current study
had a minimum power of 90% with a confidence level of
95% to detect a mean difference of 1.0 (SD: 2.7) in DALY
losses between the groups with the smallest sample of
150 participants per group as a minimum. The study
sample of the Ginerisk study included a total of 4,157
participants, but for the current analysis 1,375 participants
were excluded as information on BMD, date of diagno-
sis of osteoporosis or on HRQoL were not available.
The final population for DALY estimation consisted
of 2,782 (67%) Spanish postmenopausal women with a
diagnosis of osteoporosis (spinal BMD T-score < −2,5 ac-
cording to WHO criteria and identified by DXA) within
the two years prior to the study visit with information on
BMD, with a date of diagnosis of osteoporosis and avail-
able HRQoL values at the time of data collection. In order
to be sure that missing data could not be allocated to a
special group of participants, characteristics of the partici-
pants with a DALY value were compared univariantly with
participants without a DALY value by means of chi-square
or t-test. No significant differences between both groups
were observed in age, smoking and BMI categorized by
20 kg/m2.Disability-adjusted life-years
A detailed description on the methodology used for
DALY estimation has been described by Fox-Rushby &
Hanson [19]. DALY as a measure of the level of health is
the sum of the number of years of life lost (YLL) due to
premature mortality plus the number of years lived with a
disability (YLD). In this study undiscounted and dis-
counted DALY were estimated, using a 3% discount with-
out applying any age weighting factor [20,21].Years of life lost
YLL is an estimation of the number of years lost as a re-
sult of premature death based on a predetermined life
expectancy. Future YLL were computed for each individ-
ual participant by calculating the expected individual life
expectancy of each woman and the age of death due to
osteoporosis or severe osteoporosis. As no mortality of
women with osteoporosis or severe osteoporosis was ac-
tually observed in the Ginerisk study, the estimation of
YLL concerns an estimation of the possible premature
death of the study participants due to their condition.
For the estimation of future life years lost, the standard
life expectancy (i.e. 84.6 years for Spanish women) from
a given time until the age of death and mortality data as-
sociated with osteoporosis and severe osteoporosis were
obtained from the Spanish National Statistics Institute
[22]. It was assumed that women with a T-score > −2.5,
had a standard life expectancy similar to the general popu-
lation. Therefore YLL were only estimated for osteopor-
otic and severe osteoporotic women who showed excess
mortality due to osteoporosis. Excess mortality associated
with osteoporosis was observed for severe osteoporotic
women aged 70 years or more and showed to increase
with age. The excess mortality rates applied respectively
were: 8/100.000 for women aged 70–74, 111/100.000
women aged 75–79, 363/100.000 women aged 80–84 and
1.716/100.000 for women aged over 85. Excess mortal-
ity for osteoporotic women was lower that than for
severe osteoporotic women. The excess mortality rates
applied respectively were: 1/100.000 for women aged 60–
69, 2/100.000 women aged 75–79, 9/100.000 women aged
80–84 and 40/100.000 for women aged over 85.
For example, a woman with severe osteoporosis, with an
age falling in the category 75–79 years old, had a mortality
rate of 2 per 100.000 associated with osteoporosis. Based
on an average age of 77.5, the interpolated life expectancy
of an osteoporotic woman was estimated to be 11.61 years
which is equal to the life years women in this age category
would lose. The losses of 11.61 years per 2 out of 100,000
women in the age category 75–79 years old would lead to
((2*11.61)/100,000) approximately 0,0002 undiscounted
life years lost due to severe osteoporosis for a women in
this age category. For several age categories including
osteoporotic and severe osteoporotic women no mortality
rate was reported as no mortality due to osteoporosis was
observed in the data from the Spanish National Statistics
Institute [22].
Years of life lived with disability
YLD is an estimate of the number of years that a partici-
pant lives with disability. YLD were estimated for each
individual postmenopausal woman based on the loss in
HRQoL associated with osteoporosis and the expected
individual life span at the age of diagnosis. Data on the
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disability weights were derived from the GINERISK
study.
HRQoL data used to compute disability weights was
measured using the generic version 2 of the Medical
Outcomes Study (MOS)–Short Form (SF) with a 12 item
questionnaire (SF-12v2). The SF-12 survey generates a
physical component summary (PCS) and mental compo-
nent summary (MCS). Utility regression algorithms and
coefficients by Franks et al., [23] provided inputs for the
conversion of PCS and MCS scores of the SF-12 in
EuroQol EQ-5D interval-level scores anchored at 0
(death) and 1 (perfect health) that represent preferences
for particular health states. Mean PCS and MCS scores
were used to calculate a utility value for each individual
resulting respectively in 43.09 and 47.57, and were ad-
justed to the mean health at the same age of the popula-
tion considered in the current study. Individual disability
weights, based on the predicted utility values, were cal-
culated according to the following formula of D = 1 – Q
[24], in which D is the disability weight and Q is the
quality of life weight. The disability weight ranges from
0 to 1, in which 0 = perfect health and 1 = death.
For example YLD for a woman with an age falling in
the category 75–79 years old, were based on the number
of years that the women has lived with disability due to
her condition. A woman with an average age of 77.5 and
a time since diagnosis of 4 years was supposed to have
lived with her condition based on an interpolated life ex-
pectancy of 11.61 at the age of 77.5, for approximately
15.61 years. Her undiscounted life years lived with dis-
ability would result in 15.61 years corrected for a disabil-
ity weight based on her individual HRQoL loss. If this
patient would have had a disability weight of 0.5, then,
she would have an YLD value of 7.805.
Statistical analysis
A descriptive analysis on variables including socio-
demographics, clinical characteristics, personal back-
ground and osteoporosis therapy recorded in the Ginerisk
study was conducted, reporting absolute and relative fre-
quencies for qualitative variables and main centralization
and dispersion measures for quantitative variables. To
compare the independent samples, Pearson’s chi-square
test (χ2) (or Fisher’s exact test for 2 × 2 contingency tables
or likelihood ratio for mxn contingency tables, if neces-
sary) was used for qualitative variables, and the Student’s
T test, one-way analysis of variance (ANOVA) or its non-
parametric equivalents (Mann–Whitney U test or Kruskal-
Wallis H test) were used for quantitative variables. The
statistical significance level was established at P < 0.05.
DALY were analyzed with descriptive statistics, using uni-
variate ANOVA tables. Subsequently, paired-comparison
analyses were completed for factors showing significantgroup differences in univariate ANOVA tables. A post-hoc
Games-Howell test, was used to evaluate specific group
contrasts and to correct for unequal variances to give an
overall significance level of alpha = 0.05. All values were
presented as a mean and a 95% confidence interval.
To find out if health levels or DALY losses varied by
their association with risk factors and the use of a drug
based therapy, univariate and multivariate regression
analysis were carried out on the whole study sample.
The impact of risk factors on health levels was assessed
using an ANCOVA and MANCOVA model with BMD,
prior bone fracture, BMI < 20 kg/m2, active smoking, alco-
hol consumption (equal or above 30 g/day), family ante-
cedents of osteoporosis or/and hip fracture, rheumatoid
arthritis and receiving a corticosteroids-based therapy as
covariates. The impact of using a drug-based therapy with
a SERM was assessed using an ANCOVA model with age,
BMD, prior osteoporotic bone fractures, number of risk
factors for osteoporotic bone fracture, exercise and on-
going treatment with calcium or calcium+ vitamin D as
covariates. Data was analyzed with SPSS® version 18.0 for
Windows (SPSS; Chicago, IL).
Results
Descriptive results
In total 4,157 women participated in the Ginerisk study
of which 2,782 were postmenopausal women that had a
value for BMD (T-score) and a HRQoL score. Table 1
provides data on socio-demographics, clinical character-
istics, background with co-morbidities and osteoporosis,
for the three groups categorized according to their BMD
value into severe osteoporosis (n = 272), osteoporosis
(n = 1,958) and postmenopausal women with a current
T-score > −2.5 (n = 552). The mean age of the whole
study population was 61.15 (95% CI 60.90-61.40) years.
Significant differences were observed between the three
groups in age (P < 0.001), employment situation (P < 0.001)
and education level (P = 0.002) with the exception of en-
vironment (P = 0.973). The presence of co-morbidities in-
cluding type 1 and type 2 diabetes mellitus, hypertension,
rheumatoid arthritis, hyperthyroidism, and malabsorption
syndrome showed to be significantly different for the three
groups (P ≤ 0.01). Significant differences (P < 0.001) be-
tween the three groups were also found for the mean age
of diagnosis of osteoporosis, BMD, number of risk factors
for osteoporotic bone fractures, osteoporosis itself and
time passed since diagnosis.
Table 2 provides the data on treatment for osteopor-
osis for all three groups which consisted of hygiene and
health measures, calcium supplements, calcium+ vitamin D,
exercise, and drug therapy, the latter comprising bispho-
sphonates, SERM, and other drugs. The data showed that
most postmenopausal women independent of its BMD
value used some kind of treatment although no significant
Table 1 Socio-demographics, clinical characteristics and participant background by study group
Variable Study group by BMD
Severe osteoporosis
with prior BF (n = 272)
Osteoporosis
(n = 1,958)
T-score > −2.5
(n = 552)
F or Chi-2
(p value)₤
Socio-demographic data
Age (years) 63.3 ± 7.3 60.9 ± 7.4 59.9 ± 6.6 20.3 (p < 0.001)
Age group (%)
≤44 0.0 0.5 0.2 38.4 (p < 0.001)
45-49 1.5 3.7 4.2
50-54 9.6 13.6 16.8
55-59 21.7 28.4 31.0
60-64 28.7 24.9 25.0
≥65 38.6 28.9 22.8
Employment situation (%)
Working 28.3 41.3 45.1 37.4 (p < 0.001)
Transitory sick leave 4.0 2.2 1.6
Permanent disability 1.5 0.7 0.5
Unemployment 3.3 3.6 2.0
Retired 29.0 20.1 16.7
Housewife 33.8 32.1 34.1
Education level (%)
None 12.2 6.5 5.3 23.7 (p = 0.003)
Primary 39.6 34.4 36.6
Secondary 25.2 29.3 28.8
Undergraduate 13.3 16.7 14.5
Degree 9.6 13.2 14.9
Environment (%)
Rural 16.6 9.9 11.6 0.1 (p = 0.702)
Semi-urban 21.8 22.7 20.1
Urban 34.3 38.8 45.0
Metropolitan 27.3 28.6 23.2
Clinical characteristics
BMI (kg/m2) 25.8 ± 4.1 25.6 ± 4.3 25.7 ± 4.4 0.4 (p = 0.675)
Cigarettes/day 1.6 ± 0.7 1.6 ± 0.7 1.8 ± 0.7 2.2 (p = 0.113)
Smoking (%)
Non-smoker 67.3 67.7 66.7 1.1 (p = 0.889)
Former smoker 16.2 17.8 18.2
Smoker 16.5 14.6 15.1
Alcohol consumption, any (%) 22.2 17.5 18.7 3.7 (p = 0.156)
Alcohol consumption > 30 gr/day (%) 1.9 0.8 1.5 4.2 (p = 0.125)
Background of co-morbidities(%)
Diabetes mellitus
No 81.0 93.2 94.5 51.9 (p < 0.001)
Type I 3.7 1.2 2.6
Type II 15.3 5.6 2.9
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Table 1 Socio-demographics, clinical characteristics and participant background by study group (Continued)
Hypertension (%) 37.8 21.9 22.7 33.2 (p < 0.001)
Rheumatoid arthritis 7.6 4.3 3.7 6.9 (p = 0.031)
Anorexia nervosa 0.4 0.3 0.4 0.1 (p = 0.968)
Hyperparathyroidism 0.8 0.3 0.4 1.0 (p = 0.602)
Hyperthyroidism 3.8 2.5 1.3 5.1 (p = 0.078)
Chronic liver diseases 0.8 0.7 0.4 0.8 (p = 0.664)
Malabsorption syndrome 1.9 0.2 0.6 10.0 (p = 0.007)
Osteoporosis data
Age at diagnosis (years) 59.9 ± 6.8 58.9 ± 6.9 58 ± 6.4 8.7 (p < 0.001)
BMD (DXA) −2.9 ± 0.4 −2.8 ± 0.5 −0.9 ± 1.9 990.3 (p < 0.001)
# of risk factors for osteoporotic BF 1.9 ± 0.8 0.5 ± 0.7 0.5 ± 0.7 495.7 (p < 0.001)
# of risk factors for osteoporosis 6.9 ± 0.3 5.0 ± 1.8 4.9 ± 1.8 172.9 (p < 0.001)
Time from diagnosis (years) 3.4 ± 3.8 2.1 ± 2.8 2.1 ± 2.8 24.0 (p < 0.001)
Note: Values are mean (standard deviation) or percentage relative to total in the group. ₤Chi2 may be lineal for trend or likelihood ratio. Environment; rural
(≤10,000 inhabitants), semi-urban (>10,000 to ≤30,000 inhabitants), urban (>30,000 to ≤200,000 inhabitants) and metropolitan (>200,000 inhabitants).
BF = Bone fracture.
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Bisphosphonates and other drug treatments were more
frequently used. Significant differences exists in the use
bisphosphonates among women with severe osteopor-
osis, while a SERM was significantly more used in
women with osteoporosis or postmenopausal women
with a T-score > −2.5.
Individual DALY
DALYs were computed for 2,782 postmenopausal women,
for whom an age of diagnosis of osteoporosis, BMD
(T-score) value and HRQoL score were available. In
terms of the level of health, individual DALY losses undis-
counted and discounted were expressed in mean (95% CI)
for the total study population, and by group according
to BMD and age as shown in Table 2. Total undis-
counted DALY losses for the group with severe osteopor-
osis (Table 3) were significantly higher with 7.8 (95% CI;Table 2 Osteoporosis therapy background by study group
Variable Study group by BMD
Severe osteoporosis
with prior BF (n = 272)
Osteoporosis therapy (%)
Hygiene/health measures 90.9
Calcium supplement 12.2
Calcium + vitamin D 80.0
Exercise 45.2
Biphosphonates 61.7
SERM 26.5
Other drug therapy 12.2
Note: Values are percentage relative to total in the group. ₤Chi2 may be lineal for tr7.2-8.4) than for the group with osteoporosis and the
group with a T-score > −2.5 with respectively 5.8 (95% CI;
5.8-6.5) and 6.2 (95% CI; 5.8-6.5) (P < 0.001). Similar re-
sults were observed when future DALY losses were dis-
counted with 3%.
DALY losses in postmenopausal women <65 years of age
undiscounted and discounted were higher than for post-
menopausal women ≥ 65 years of age for all three study
groups (Table 2). DALY losses were significantly higher for
the group with severe osteoporosis aged <65 years com-
pared to the group with osteoporosis and the group with a
T-score > −2.5. For postmenopausal women ≥ 65 years of
age a significantly higher losses in undiscounted and dis-
counted DALY was observed for the severe osteoporotic
group compared to with the group with osteoporosis.
Only a significant difference in discounted DALY losses
was observed between the severe osteoporotic group and
the group with a T-score > −2.5.Osteoporosis
(n = 1958)
T-score > −2.5
(n = 552)
F or Chi-2
(p value)₤
91.4 89.6 1.4 (p = 0.489)
10.4 14.5 5.6 (p = 0.062)
81.9 72.7 16.8 (p < 0.001)
42.3 42.3 0.7 (p = 0.694)
49.0 43.5 19.1 (p < 0.001)
42.3 47.1 26.3 (p < 0.001)
7.0 5.5 10.0 (p = 0.007)
end or likelihood ratio.
Table 3 DALY losses in mean (CI95%), undiscounted and discounted by BMD and age
Individual DALYs undiscounted All ages Women < 65 years of age Women ≥ 65 years of age
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Severe osteoporosis with prior BF (n = 272) 7.8a,b (7.2 8.4) 9.0a,b (8.2, 9.8) 5.9d (5.3, 6.6)
Osteoporosis (n = 1,958) 5.8c (5.6, 6.0) 6.1c (5.8, 6.4) 4.9e (4.6, 5.2)
T-score > −2.5 (n = 552) 6.2c (5.8, 6.2) 6.5c (6.0, 6.9) 5.0 (4.6, 5.5)
Total study population (n = 2,788) 6.1 (5.9, 6.2) 6.4 (6.2, 6.7) 5.1 (4.9, 5.3)
Individual DALYs discounted All ages Women < 65 years Women ≥ 65 years of age
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Severe osteoporosis with prior BF (n = 272) 5.5a,b (5.1, 5.9) 6.1a,b (5.5, 6.6) 4.6d,f (4.2, 5.1)
Osteoporosis (n = 1,958) 4.0c (3.9, 4.1) 4.1c (3.9, 4.2 3.8e (3.6, 4.0)
T-score > −2.5 (n = 552) 4.2c (4.0, 4.4) 4.3c (4.0, 4.6) 3.9g (3.5, 4.3)
Total study population (n = 2,788) 4.2 (4.1, 4.3) 4.3 (4.2, 4.4) 3.9 (3.8, 4.1)
Note: aP < 0.001 versus osteoporotics; bP < 0.001 versus postmenopausal women T > −2.5; cP < 0.001 versus severe osteoporosis with prior BF; dP = 0.01 versus
osteoporotics; eP = 0.01 versus severe osteoporosis with prior BF; fP < 0.05 postmenopausal women T > −2.5; gP < 0.05 versus severe osteoporotics with prior BF.
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The results of the covariate and multivariate regression
analysis to determine the impact of risk factors on DALY
losses in the total study population are represented in
Table 4. The results showed that not having a prior osteo-
porotic bone fracture lead to significantly lower undis-
counted DALY losses (Constant = −2.0), as well as less
alcohol consumption than 30 g/day (Constant = −2.4), not
having rheumatoid arthritis (Constant = −2.9), no priorTable 4 Variables associated with DALY losses adjusted by ris
Variables* ANCOVAa
Constant (95% CI) P-valu
BMD 0.1 (0.0, 0.3) 0.066
Prior osteoporosis BF (No) −2.0 (−2.5, −1.4) <0.001
BMI < 20 kg/m2 (No) 0.0 (−0.7, 0.8) 0.898
Smoking status (Non-smoker) −0.2 (−0.7, 0.2) 0.336
Alcohol consumption ≥30 g/day (No) −2.4 (−4.0, −0.8) 0.003
Rheumatoid arthritis (No) −2.9 (−3.6, −2.1) <0.001
Family antecedents of osteoporosis (No) −0.4 (−0.7, 0.0) 0.033
Use of corticosteroids (No) −3.6 (−5.9, −1.4) 0.002
Variables ANCOVAa
Constant (95% CI) P-valu
BMD 0.1 (0.0, 0.2) 0.102
Prior osteoporosis BF (No) −1.5 (−1.8, −1.1) <0.001
BMI < 20 kg/m2 (No) 0.2 (−0.3, 0.7) 0.462
Smoking status (Non-smoker) 0.0 (−0.3, 0.3) 0.793
Alcohol consumption ≥30 g/day (No) −1.5 (−2.5, −0.4) 0.008
Rheumatoid arthritis (No) −2.2 (−2.7, −1.6) <0.001
Family antecedents of osteoporosis (No) −0.2 (−0.4, 0.1) 0.132
Use of corticosteroids (No) −2.3 (−3.9, −0.8) 0.002
Notes: aModel build for each factor adjusted by BMD and prior osteoporotic BF; bM
global mean (95% CI) for the undiscounted DALYs multivariate model was 14.6 (12.
the reference category is given between brackets.family antecedents of osteoporosis (Constant = −0.4), and
not using corticosteroids (Constant = −3.6). Similar associ-
ations were observed for undiscounted and discounted
DALY losses with the exception of the impact of family
antecedents of osteoporosis. Table 4 also shows the results
of the MANCOVA analysis by adding all risk factors to
the model at the same time. Having a higher BMD
value, a prior osteoporotic bone fracture, rheumatoid
arthritis, family antecedents of osteoporosis and the use ofk factors
MANCOVAb Undiscounted DALYs
e Constant (95% CI) P-value Mean (95% CI) P-value
0.2 (0.1, 0.3) 0.004 - - -
−1.8 (−2.3, −1.2) <0.001 - - -
- - - 6.1 (5.2, 6.9) -
- - - 6.0 (5.9, 6.2) -
- - - 6.2 (5.9, 6.0) P < 0.01
−2.8 (−3.5, −2.0) <0.001 5.9 (5.8, 6.1) P < 0.01
−0.4 (−0.8, −0.1) 0.016 5.8 (5.6, 6.0) P < 0.05
−3.6 (−5.9, −1.2) 0.003 6.0 (5.9, 6.2) P < 0.01
MANCOVAb Undiscounted DALYs
e Constant (95% CI) P-value Mean (95% CI) P-value
0.1 (0.0, 0.2) 0.004 - - -
−1.4 (−1.8, −1.1) <0.001 - - -
- - - 4.1 3.5, 4.6 -
- - - 4.2 4.1, 4.3 -
- - - 4.2 4.1, 4.3 P < 0.01
−2.1 (−2.6, −1.6) <0.001 6.4 5.8, 4.2 P < 0.01
- - - 4.0 3.9, 4.7 -
−2.2 (−3.7, −0.6) 0.007 4.2 4.1, 4.3 P < 0.01
odel calculated with all the factors at the same time; NS = Not significant. The
2; 17.1) and 10.0 (8.3; 11.6) for the discounted DALYs. *For categorical variables
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A similar model was found for discounted DALY losses,
with the exception of the impact of family antecedents of
osteoporosis.
Table 5 shows the results of the impact of a drug-
based therapy with SERM on DALY losses for the total
study population using a covariate regression analysis. Not
using a SERM showed to increase DALY losses (Constant =
0.6) as well as having risk factors for osteoporosis (Con-
stant = 0.3). Being younger (Constant = −0.1) and not hav-
ing a prior osteoporotic bone fracture (Constant = −1.6)
showed to reduce DALY losses. Similar associations with
the use of a SERM were observed for discounted DALY
losses.
Discussion
The most innovative part of this study is the use of indi-
vidual DALY losses to measure the level of health in
postmenopausal women according to their BMD value
from the data collected by the GINERISK study. The
collection of generic HRQoL allowed us to compute dis-
ability weights for the estimation of individual YLD due
to osteoporosis. Generic HRQoL showed to be worse in
severe osteoporotic participants compared with the rest
of the study population, in relation to the SpanishTable 5 Variables associated with DALY losses adjusted
by drug based therapy
Undiscounted DALYs ANCOVA
Variables* Constant 95% CI P-value
BMD 0.1 (−0.3, 0.5) 0.607
Age −0.1 (−0.1, −0.1) <0.001
Prior osteoporotic BF (No) −1.6 (−2.3, −0.9) <0.001
Prior treatment with calcium (No) −0.6 (−0.7, 0.2) 0.121
Prior treatment with
calcium + vitamin D (No)
−0.1 (−0.7, 0.6) 0.877
Exercise (No) 0.3 (−0.1, 0.7) 0.188
Risk factors for osteoporosis 0.3 (0.1, 0.6) 0.018
Use of SERM (No) 0,6 (0.1, 1.0) 0.010
Discounted DALYs ANCOVA
Variables* Constant 95% CI P-value
BMD 0.1 (−0.2, 0.3) 0.567
Age 0.0 0.0 0.003
Prior osteoporotic BF (No) −1.1 (−1.6, −0.6) <0.001
Prior treatment with calcium (No) −0.5 (−1.0, 0.1) 0.090
Prior treatment with
calcium + vitamin D (No)
−0.1 (−0.5, 0.4) 0.831
Exercise (No) 0.2 (−0.1, 0.5) 0.189
Risk factors for osteoporosis 0.2 (0.3, 0.4) 0.019
Use of SERM (No) 0.4 (0.1, 0.7) 0.010
*For categorical variables the reference category is given between brackets.general female population [18]. Accordingly, as observed
in this study, YLD were higher for severe osteoporotic
participants than for osteoporotic participants and post-
menopausal participants with a T-score > −2.5 resulting
in higher DALY losses which is in line with literature
[5,25,26] . Although no specific information on the type
of prior bone fractures was known for participants with
severe osteoporosis in the Ginerisk study, data from lit-
erature [27] showed that mortality risk increases and re-
mains higher than the age-matched general population
mortality rate for several years following hip and verte-
bral fractures which explains why premature death or
YLL in severe osteoporotic participants is higher than in
the other groups.
DALY losses in this study were presented undis-
counted and 3% discounted without applying an age
weighting factor according to the methodology described
by Fox-Rushby & Hanson [19]. The 3% discount rate is
similar to the rate applied in the World Bank and Global
Burden of Disease project [28,29]. No age-weighting was
applied to give DALY losses different values at different
ages which imply that the relative value of a year of life
rises rapidly from birth to a peak in the early twenties,
after which it declines steadily [30]. This might be a
limitation of the study but on the other hand applying
age-weights has also been criticised and evaluated as un-
acceptable on equity grounds [31], not empirically based
[32] and adding complexity to burden of disease analyses
that obscures the method and makes little overall differ-
ence to the rankings of diseases and injuries.
In this study, DALY losses were shown to be affected by
risk factors for osteoporosis or the use of a drug based
treatment with SERM. An explanation for the association
between DALY and risk factors or using a drug-based
treatment with SERM is that both may affect HRQoL and
consequentially DALY losses. Similar associations of risk
factors like age and prior vertebral and non-vertebral bone
fractures and HRQoL were observed in the Fravo Study
[25] among postmenopausal women living in the city of
Valencia. Concerning the use of a drug based treatment
with a SERM in the HORIZON Pivotal Fracture Trial
(HORIZON-PFT) it was shown that non-SERM users had
poorer general health, and on the other hand long-term
drug treatment of osteoporosis has been associated with
an improvement in some domains of HRQoL [33]. Al-
though it was shown that HRQoL directly affected DALY
losses in this study its mechanism is not exactly known.
A limiting factor of this study concerns the methodology
used to estimate disability weights based on HRQoL data
from the GINERISK study to compute DALY. Methods to
estimate utility values from HRQoL data were taken from
Franks et al. [23], which used a model that explained 63%
of variance in EQ-5D scores. The use of different algo-
rithms and coefficients as presented in Mortimer & Segal
Darbà et al. BMC Public Health  (2015) 15:324 Page 9 of 10[34] could have affected disutility weights. Another limita-
tion to be addressed is the cross-sectional design of the
GINERISK study which provided data input for DALY cal-
culation. The impact of co-morbidities and life style factors
on HRQoL and life expectancy was not assessed and no
data in the Ginerisk study was collected on the type of
bone fractures. Worse HRQoL could, apart from being
caused by osteoporotic bone fractures dependent on its
type, also be affected by co-morbidities or lifestyle. On the
contrary, specific drugs taken by participants for co-
morbities could also have affected the HRQoL of postmen-
opausal women in the Ginerisk study, though no informa-
tion was collected on other medication than osteoporosis
treatment. Therefore the relationship of type of bone frac-
ture, co-morbities and its drug treatment, and life style
with DALY losses by BMD and/or age category has not
been established directly and should be considered as a
study limitation.
Another limitation concerns the non-availability of
data on mortality for the women in the Ginerisk study.
YLL in our study are an estimation of premature mortal-
ity due to osteoporosis or severe osteoporosis. To esti-
mate the potential individual YLL of an individual
participant in the Ginerisk study it is necessary to have
information on the average age of death due to their
condition. To give estimations for the future individual
life years lost of the participants in the Ginerisk study,
their mortality was based on Spanish mortality data due
to osteoporosis published by the National Statistics Insti-
tute by estimating the average life years lost for each
participant due to osteoporosis or severe osteoporosis
according to their age at the study visit. Based on the
Spanish mortality rates it was estimated that YLL due to
osteoporosis or severe osteoporosis were almost neglect-
ible compared to YLD. It needs to be stated that YLL es-
timated in this study concerns a future estimation and
might differ based on accurate individual mortality data
from the women that participated in the Ginerisk study.
This data can only be collected by means of a longitu-
dinal study over time and not in a cross-sectional study
design as used for the Ginerisk study.
In total DALY were computed for 2,782 out of 4,157
Spanish postmenopausal women having an age of diag-
nosis of osteoporosis, a BMD (T-score) value and a
HRQoL score. To examine if significant differences be-
tween women without a computed value for DALY and
with a value for DALY existed, a logistic multivariate
model was used. The multivariate model which examined
the lack of data for computing DALY included BMD and
the number of risk factors for osteoporotic bone fracture
(% of right classification 85.6%) which were also tested in
this study to estimate the relation of risk factors for partic-
ipants with undiscounted and discounted DALY. From
this multivariate model and the knowledge that thesemodels are based on likelihood, DALY estimations in this
study are valid under the assumption missing at random.
It was not possible though to demonstrate that the data
was missing at random, therefore the lack of the data
is a limitation for this study which could have produced
a lack of precision in the coefficient estimates. A possible
bias could also exist in the participant selection for the
GINERISK study as all women were attending outpatient
gynaecology clinics.
To our knowledge this study represents the first estima-
tion of individual DALY losses for postmenopausal women
according to BMD in Spain. Mean DALY losses for the
whole study population was estimated at 6.1 (95% CI 5.9-
6.2). Although data on DALY losses for the total Spanish
population are missing it was estimated that mean DALY
losses were precise with a variation of 0.16 DALY for the
bilateral 95% based on approximately 2 million women ac-
tually suffering from osteoporosis in Spain [35]. Based on
this data one has to convey that osteoporosis in postmeno-
pausal women faces an important burden of disease, par-
ticularly when a bone fracture has already occurred [34].
In the Global Burden of Disease study, osteoporosis (2.0
million DALY) accounted for 1.75% of the total DALY
losses for non-communicable diseases in Europe [36,37].
Other chronic diseases including asthma (1.4 million
DALY), migraine (1.2 million DALY), hypertensive heart
disease (1.2 million DALY), and rheumatoid arthritis (1.0
million DALY) were outranked by DALY losses due to
osteoporosis. Osteoporosis has shown to constitute a con-
siderable burden to society on a global and European level
which emphasizes the health impact of this disease. Our
findings have implications for future health economic ana-
lyses and policy-making related to care of osteoporosis,
taking into account the full consequences of osteoporosis
on the patient further than just its consequences in terms
of fractures which cannot be controlled by clinicians or
the healthcare system as it is traditionally defined.
Conclusion
DALY losses were considerable amongst postmenopausal
women with osteoporosis. Not having a prior bone frac-
ture, being older, having less osteoporotic risk factors and
using a SERM have been linked to less DALY losses. Risk
factors affecting undiscounted and discounted DALY in-
cluded alcohol consumption, rheumatoid arthritis and the
use of corticosteroids.
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